Total Payments
$2,456
2024 Payments
$186.44
Companies
6
Transactions
15
Medicare Patients
785
Medicare Billing
$72,076
Payment Breakdown by Category
Research$2,108 (85.9%)
Food & Beverage$290.50 (11.8%)
Education$56.92 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,108 | 2 | 85.9% |
| Food and Beverage | $290.50 | 11 | 11.8% |
| Education | $56.92 | 2 | 2.3% |
Payments by Type
Research
$2,108
2 transactions
General
$347.42
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $2,108 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $209.56 | 9 | $0 (2024) |
| Daiichi Sankyo Inc. | $57.31 | 1 | $0 (2024) |
| Epizyme, Inc., | $45.00 | 1 | $0 (2021) |
| Merck Sharp & Dohme LLC | $23.63 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $186.44 | 6 | Novartis Pharmaceuticals Corporation ($105.50) |
| 2023 | $2,138 | 4 | Eli Lilly and Company ($2,072) |
| 2021 | $56.92 | 2 | Epizyme, Inc., ($45.00) |
| 2019 | $17.49 | 1 | Novartis Pharmaceuticals Corporation ($17.49) |
| 2018 | $36.55 | 1 | Eli Lilly and Company ($36.55) |
| 2017 | $20.37 | 1 | Novartis Pharmaceuticals Corporation ($20.37) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $57.31 | General |
| Category: ONCOLOGY | ||||||
| 02/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Oncology | ||||||
| 01/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: ONCOLOGY | ||||||
| 01/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: Oncology | ||||||
| 01/16/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $32.10 | General |
| Category: Immunology | ||||||
| 11/10/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Oncology | ||||||
| 09/22/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Oncology | ||||||
| 06/09/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Oncology | ||||||
| 06/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $2,071.83 | Research |
| Study: EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/02/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $45.00 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.49 | General |
| 03/29/2018 | Eli Lilly and Company | — | — | In-kind items and services | $36.55 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 09/21/2017 | Novartis Pharmaceuticals Corporation | INC280 (Drug), MEKINIST, TAFINLAR | Food and Beverage | In-kind items and services | $20.37 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $2,072 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $36.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 166 | 264 | $64,560 | $14,196 |
| 2022 | 4 | 184 | 267 | $70,860 | $16,410 |
| 2021 | 6 | 206 | 301 | $88,415 | $21,383 |
| 2020 | 6 | 229 | 320 | $98,631 | $20,087 |
Total Patients
785
Total Services
1,152
Medicare Billing
$72,076
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 90 | 154 | $33,110 | $7,527 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 51 | $16,320 | $3,424 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 20 | $8,500 | $2,171 | 25.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 31 | 39 | $6,630 | $1,073 | 16.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 103 | 145 | $31,175 | $6,840 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 48 | 77 | $24,640 | $5,753 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 29 | $12,325 | $3,489 | 28.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 16 | 16 | $2,720 | $329.65 | 12.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 97 | 138 | $29,670 | $6,795 | 22.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 48 | 84 | $26,880 | $6,114 | 22.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $15,125 | $3,908 | 25.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 27 | $11,475 | $3,349 | 29.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 15 | $3,225 | $903.75 | 28.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 12 | 12 | $2,040 | $312.02 | 15.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 89 | 147 | $47,040 | $8,395 | 17.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 45 | $19,125 | $4,014 | 21.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 70 | 77 | $16,555 | $3,207 | 19.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 19 | 19 | $11,495 | $2,725 | 23.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 14 | 16 | $2,640 | $1,067 | 40.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 15 | 16 | $1,776 | $679.07 | 38.2% |
About Dr. Gayathri Nagaraj, MD
Dr. Gayathri Nagaraj, MD is a Medical Oncology healthcare provider based in Loma Linda, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1346402286.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gayathri Nagaraj, MD has received a total of $2,456 in payments from pharmaceutical and medical device companies, with $186.44 received in 2024. These payments were reported across 15 transactions from 6 companies. The most common payment nature is "" ($2,108).
As a Medicare-enrolled provider, Nagaraj has provided services to 785 Medicare beneficiaries, totaling 1,152 services with total Medicare billing of $72,076. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Loma Linda, CA
- Active Since 07/01/2008
- Last Updated 10/17/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346402286
Products in Payments
- KISQALI (Drug) $94.78
- Enhertu (Drug) $57.31
- TAZVERIK (Drug) $45.00
- PIQRAY (Drug) $44.82
- Fabhalta (Drug) $32.10
- KEYTRUDA (Biological) $23.63
- INC280 (Drug) $20.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.